We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Angola has introduced a new malaria drug in the handful of provinces most affected by the disease, including Luanda, Benguela, Huambo e Uije and possibly Kwanza-Sul and Bengo.
The groups Medecins Sans Frontieres (MSF) and the Canadian HIV/AIDS Legal Network have said they are encouraged by Canadian Health Minister Tony Clement's statement at the International AIDS Conference that the government will review the Jean Chretien Pledge to Africa.
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has announced changes to its system for providing scientific and regulatory advice to clinical trial sponsors.
U.S.-based drugmaker Gilead, which manufactures the HIV drug Viread, has announced the drug will soon be available in India for approximately $1 per day, compared with generic versions currently available for more than $1,200 per year.
Pharmaceutical company, Zenotech Laboratories Ltd on Saturday said it will consider allotment of 20 lakh equity shares to Ranbaxy Laboratories Ltd on a preferential basis for Rs 20 crore.
Sumitomo Chemical Co. and its pharmaceutical unit Dainippon Sumitomo Pharma Co. said Monday that they have reached a settlement with Pfizer Inc.'s subsidiaries over licensing of a hypertension drug called Amlodin.
Ranbaxy Laboratories Limited (Ranbaxy) announced the launch of its brand Soliten (Solifenacin), in the Indian market for the management of chronic urological disorder.
China Biopharmaceuticals Holdings, Inc., a leading Chinese pharmaceutical company focused on the development, manufacturing and distribution of innovative drugs in China, announced that it has completed all required clinical trials for one of its new drugs, Nafamostate Mesilate and is waiting for final manufacturing and marketing approval from the State Food and Drug Administration of China (SFDA).
Indian pharmaceutical firm Ranbaxy Laboratories Ltd. is said to be close to acquiring Russian generic drug maker Akrikhin for nearly $100 million, according to speculative media reports.